MedTrace Logo

A Phase I Study of TS-142 in Healthy Participants (Repeated Doses)

NCT04169906 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-02-28

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety, pharmacokinetics, and pharmacodynamics of repeated dosing of TS-142 when administered once daily to healthy Japanese non-elderly participants.

Conditions

  • Healthy Volunteer

Interventions

DRUG

Placebo

Participants will receive placebo once daily for 7 consective days

DRUG

TS-142, 10 mg

Participants will receive 10 mg of TS-142 once daily for 7 consective days

DRUG

TS-142, 20 mg

Participants will receive 20 mg of TS-142 once daily for 7 consective days

DRUG

TS-142, 30 mg

Participants will receive 30 mg of TS-142 once daily for 7 consective days

Sponsors & Collaborators

  • Taisho Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Shigeru Okuyama · Taisho Pharmaceutical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
20 Years
Max Age
39 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-06
Primary Completion
2016-10-08
Completion
2016-10-08

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04169906 on ClinicalTrials.gov